| 4 |
| RTW INVESTMENTS, LP |
| 4.3M |
| $377.5M |
| +1.9% |
| 4.896% |
| 3.22% |
| 5 | Paradigm Biocapital Advisors LP | 3.8M | $341.0M | +96.2% | 4.423% | 6.38% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4M | $306.2M | +12.8% | 3.971% | 0.01% |
| 7 | STATE STREET CORP | 3.1M | $271.4M | +17.3% | 3.521% | 0.00% |
| 8 | Venrock Adviser, LLC | 3.0M | $265.0M | -19.0% | 3.438% | 8.04% |
| 9 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.8M | $248.5M | +0.3% | 3.223% | 1.44% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $239.3M | +48.9% | 2.950% | 0.01% |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $206.9M | +298.2% | 2.683% | 0.01% |
| 12 | Capital World Investors | 2.3M | $205.6M | +247.4% | 2.666% | 0.02% |
| 13 | Jupiter Topco LLC | 2.2M | $195.9M | — | 2.541% | 0.08% |
| 14 | TCG Crossover Management, LLC | 1.9M | $168.7M | 0.0% | 2.189% | 4.06% |
| 15 | TANG CAPITAL MANAGEMENT LLC | 1.9M | $168.0M | 0.0% | 2.179% | 7.63% |
| 16 | BANK OF AMERICA CORP /DE/ | 1.8M | $157.8M | +44.8% | 2.047% | 0.01% |
| 17 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7M | $152.9M | — | 1.983% | 0.21% |
| 18 | WELLINGTON MANAGEMENT GROUP LLP | 1.6M | $140.4M | -13.3% | 1.821% | 0.02% |
| 19 | GOLDMAN SACHS GROUP INC | 1.5M | $131.2M | +447.6% | 1.702% | 0.01% |
| 20 | FRANKLIN TEMPLETON INC | 1.5M | $130.8M | +66.8% | 1.696% | 0.03% |
| 21 | Remedium Capital Partners, LLC | 1.5M | $130.0M | +0.5% | 1.686% | 28.78% |
| 22 | Affinity Asset Advisors, LLC | 1.3M | $113.6M | 0.0% | 1.473% | 5.13% |
| 23 | JPMORGAN CHASE & CO | 1.1M | $98.9M | +11.6% | 1.259% | 0.01% |
| 24 | Holocene Advisors, LP | 1.0M | $90.1M | — | 1.169% | 0.20% |
| 25 | MARSHALL WACE, LLP | 992K | $88.0M | +612.1% | 1.142% | 0.07% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SYRE — a direct measure of their conviction.
| 104.39% |
| +5.43 pp |
| $994M |
| 26% |
| Q4 2024 | 132 | +11% | 98.96% | 1.02 pp | $1.35B | 8.2% |
| Q3 2024 | 119 | — | 99.98% | — | $1.47B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
87 institutions opened new positions in SYRE during Q2 2026, while 21 fully exited. 153 added to existing positions and 19 trimmed.
SYRE institutional ownership rose by 4.35 percentage points quarter-over-quarter, with a net change of +67 holders.
The top 10 institutions account for 50.2% of all reported 13F value in SYRE, and the top 25 account for 76.4%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Spyre Therapeutics, Inc. (SYRE) Institutional Ownership